Tela Bio Stock Today
TELA Stock | USD 1.50 0.05 3.45% |
PerformanceWeakest
| Odds Of DistressRisky
|
Tela Bio is trading at 1.50 as of the 30th of September 2025, a 3.45 percent increase since the beginning of the trading day. The stock's open price was 1.45. Tela Bio has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 2nd of July 2025 and ending today, the 30th of September 2025. Click here to learn more.
Business Domain Health Care Equipment & Services | IPO Date 8th of November 2019 | Category Healthcare | Classification Health Care |
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patients anatomy. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania. The company has 39.62 M outstanding shares of which 413.67 K shares are at this time shorted by private and institutional investors with about 4.97 trading days to cover. More on Tela Bio
Moving against Tela Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Tela Stock Highlights
President Director | Jeffrey Blizard | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Business Concentration | Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Health Care Equipment & Supplies, Medical Devices, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsTela Bio can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Tela Bio's financial leverage. It provides some insight into what part of Tela Bio's total assets is financed by creditors.
|
Tela Bio (TELA) is traded on NASDAQ Exchange in USA. It is located in 1 Great Valley Parkway, Malvern, PA, United States, 19355 and employs 209 people. Tela Bio is listed under Health Care Equipment & Supplies category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 57.44 M. Tela Bio conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. The entity has 39.62 M outstanding shares of which 413.67 K shares are at this time shorted by private and institutional investors with about 4.97 trading days to cover.
Tela Bio currently holds about 27.73 M in cash with (41.59 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.9, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Tela Bio Probability Of Bankruptcy
Ownership AllocationTela Bio shows a total of 39.62 Million outstanding shares. The majority of Tela Bio outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Tela Bio to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Tela Bio. Please pay attention to any change in the institutional holdings of Tela Bio as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Tela Ownership Details
Tela Stock Institutional Holders
Instituion | Recorded On | Shares | |
Blackrock Inc | 2025-06-30 | 458.5 K | |
Geode Capital Management, Llc | 2025-06-30 | 337.9 K | |
Ubs Group Ag | 2025-06-30 | 245.5 K | |
Paradigm Capital Management, Inc. | 2025-06-30 | 200 K | |
Birchview Capital, Lp | 2025-06-30 | 155 K | |
Up Strategic Wealth Investment Advisors Llc | 2025-06-30 | 99.9 K | |
Northern Trust Corp | 2025-06-30 | 94.1 K | |
Renaissance Technologies Corp | 2025-06-30 | 67.3 K | |
State Street Corp | 2025-06-30 | 63.4 K | |
Nantahala Capital Management, Llc | 2025-06-30 | 5.1 M | |
Essex Woodlands Health Ventures | 2025-06-30 | 4.1 M |
Tela Bio Historical Income Statement
Tela Stock Against Markets
Tela Bio Corporate Management
Taylor Ocasio | General Secretary | Profile | |
Antony Koblish | President, Cofounder | Profile | |
Louisa Smith | Investor Officer | Profile | |
Skott Greenhalgh | Chief Officer | Profile | |
Jennifer Armstrong | Senior Resources | Profile | |
Christopher Smith | VP Sales | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tela Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Tela Stock refer to our How to Trade Tela Stock guide.You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tela Bio. If investors know Tela will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tela Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.06) | Revenue Per Share | Quarterly Revenue Growth 0.255 | Return On Assets | Return On Equity |
The market value of Tela Bio is measured differently than its book value, which is the value of Tela that is recorded on the company's balance sheet. Investors also form their own opinion of Tela Bio's value that differs from its market value or its book value, called intrinsic value, which is Tela Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tela Bio's market value can be influenced by many factors that don't directly affect Tela Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tela Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Tela Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tela Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.